|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.64 USD | -.--% |
|
+1.93% | -61.60% |
| 05-30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
| 05-21 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
SAB Biotherapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 23.9 million compared to USD 60.88 million a year ago. Net loss was USD 18.74 million compared to USD 17.14 million a year ago.
Basic loss per share from continuing operations was USD 4.3 compared to USD 6.3 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.60% | 24.36M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
SAB BIOTHERAPEUTICS, INC. 
